ReviewAsian journal of urology2019
Contemporary approach to active surveillance for favorable risk prostate cancer.
Review in Asian journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Accuracy of Contemporary Selection Criteria in Prostate Cancer Patients Eligible for Active Surveillance: A Bayesian Network Meta-Analysis.Frontiers in oncology · 2021Pooled it
- A feasibility study of a psycho-educational support intervention for men with prostate cancer on active surveillance.Cancer reports (Hoboken, N.J.) · 2020Trial
- Focal therapy in localized prostate cancer: moving from therapeutic enthusiasm to structured stewardship.Annals of medicine and surgery (2012) · 2026Article
- Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance.Clinical genitourinary cancer · 2024Article
- PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice.Asian journal of andrology · 2024Article
- Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts.The Journal of urology · 2024Article
- Article
- Urinary marker panels for aggressive prostate cancer detection.Scientific reports · 2022Article
- Using deep learning to detect patients at risk for prostate cancer despite benign biopsies.iScience · 2022Article
- Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.Cancer reports (Hoboken, N.J.) · 2022Article
- Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients.British journal of cancer · 2022Article
- Adult preventive vaccines with other synergistic lifestyle options: is it time to add these ancillary benefits to the overall AS management checklist?World journal of urology · 2022Review
- Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.International journal of nanomedicine · 2021Article
- The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs.Nature reviews. Urology · 2020Review
- Active Surveillance of Prostate Cancer Using Multiparametric Magnetic Resonance Imaging: A Review of the Current Role and Future Perspectives.Medical science monitor : international medical journal of experimental and clinical research · 2020Review
- Towards personalized prostate cancer screening.Advances in laboratory medicine · 2020Review
- Hypofractionation in prostate cancer radiotherapy: a step forward towards clinical routine.Translational andrology and urology · 2019Article
- Article
- Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer.Cancers · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approach to favorable risk prostate cancer known as "active surveillance" was first described explicitly in 2002. This was a report of 250 patients managed with a strategy of expectant management, with serial prostate-specific antigen and periodic biopsy, and radical intervention advised for patients who were re-classified as higher risk. This was initiated as a prospective clinical trial, complete with informed consent, beginning in 2007. Thus, there are now 20 years of experience with this approach, which has become widely adopted around the world. In this chapter, we will summarize the biological basis for active surveillance, review the experience to date of the Toronto and Hopkins groups which have reported 15-year outcomes, describe the current approach to active surveillance in patients with Gleason score 3 + 3 or selected patients with Gleason score 3 + 4 with a low percentage of Gleason pattern 4 who may also be candidates, enhanced by the use of magnetic resonance imaging, and forecast future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.